GlassScriptPhysician profile
Ashley Poole
NPI 1053848788
$2,501.46
in general payments reported to CMS, 2019-2025
22 companies · $871 in 2025
The $871 reported for 2025 was more than what 78% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $443 · 2022: $391 · 2023: $243 · 2024: $553 · 2025: $871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,667.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $488.81 | 2021-2022 | |
| Pfizer INC. | $376.39 | 2023-2025 | |
| Abbvie INC. | $242.08 | 2023-2025 | |
| Lilly USA, LLC | $197.32 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $180.79 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $178.35 | 2023-2025 | Evenity, Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $121.48 | 2021-2024 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $82.33 | 2024-2025 | Breztri, Farxiga |
| Impulse Dynamics (USA) INC. | $82.04 | 2022 | |
| Medtronic, INC. | $77.62 | 2023-2024 | Interstim |
| Corium, LLC | $66.06 | 2022 | |
| Novo Nordisk INC | $65.58 | 2023-2025 | Ozempic, Rybelsus |
| Xeris Pharmaceuticals, INC. | $64.51 | 2024-2025 | Gvoke Hypopen |
| Idorsia Pharmaceuticals US INC | $62.92 | 2023-2024 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $57.19 | 2023-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $32.46 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $31.98 | 2021 | |
| Tris Pharma INC | $21.24 | 2021 | |
| Glaxosmithkline, LLC. | $20.78 | 2022 | |
| Sumitomo Pharma America, INC. | $20.07 | 2025 | Gemtesa |
| Alk-Abello, INC | $15.92 | 2021 | |
| Phathom Pharmaceuticals, INC. | $15.54 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Poole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.